These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6126231)

  • 1. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population.
    Dunlop SR; Shea PA; Hendrie HC
    Biol Psychiatry; 1982 Aug; 17(8):929-36. PubMed ID: 6126231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
    Lindenmayer JP; Smith D; Katz I
    J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
    Harris PQ; Brown SJ; Friedman MJ; Bacopoulos NG
    Biol Psychiatry; 1984 Jun; 19(6):849-60. PubMed ID: 6146355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic-refractory patients and their drug plasma levels.
    Berrios GE
    Encephale; 1982; 8(4):465-85. PubMed ID: 6129961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
    Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
    J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
    Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
    J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.
    Garver DL; Dekirmenjian H; Davis JM; Casper R; Ericksen S
    Am J Psychiatry; 1977 Mar; 134(3):304-7. PubMed ID: 14514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haloperidol plasma and red blood cell levels and clinical antipsychotic response.
    Garver DL; Hirschowitz J; Glicksteen GA; Kanter DR; Mavroidis ML
    J Clin Psychopharmacol; 1984 Jun; 4(3):133-7. PubMed ID: 6736272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone.
    Shimoda K; Someya T; Morita S; Hirokane G; Yokono A; Shibasaki M; Takahashi S
    Psychiatry Clin Neurosci; 1998 Oct; 52(5):535-40. PubMed ID: 10215017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
    Bergemann N; Kopitz J; Kress KR; Frick A
    Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenic thinking and neuroleptic dosage.
    Puente AE; Andersson C
    J Clin Psychol; 1987 Mar; 43(2):189-97. PubMed ID: 2883201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.